155 related articles for article (PubMed ID: 15303821)
1. Long-term control of hypercalcaemia in an infant with williams-Beuren syndrome after a single infusion of biphosphonate (Pamidronate).
Oliveri B; Mastaglia SR; Mautalen C; Gravano JC; Pardo Argerich L
Acta Paediatr; 2004 Jul; 93(7):1002-3. PubMed ID: 15303821
[TBL] [Abstract][Full Text] [Related]
2. Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome.
Baştuğ F; Nalçacıoğlu H; Baş VN; Tekatlı-Çelik B; Çetinkaya H; Yel S
Turk J Pediatr; 2018; 60(2):210-215. PubMed ID: 30325132
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D intoxication and hypercalcaemia in an infant treated with pamidronate infusions.
Ezgu FS; Buyan N; Gündüz M; Tümer L; Okur I; Hasanoglu A
Eur J Pediatr; 2004 Mar; 163(3):163-5. PubMed ID: 14714183
[TBL] [Abstract][Full Text] [Related]
4. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
Cagle AP; Waguespack SG; Buckingham BA; Shankar RR; Dimeglio LA
Pediatrics; 2004 Oct; 114(4):1091-5. PubMed ID: 15466114
[TBL] [Abstract][Full Text] [Related]
5. Severe hypercalcemia associated with Williams syndrome successfully treated with pamidronate infusion therapy.
Sangun O; Dundar BN; Erdogan E
J Pediatr Endocrinol Metab; 2011; 24(1-2):69-70. PubMed ID: 21528818
[TBL] [Abstract][Full Text] [Related]
6. Importance of dietary calcium and vitamin D in the treatment of hypercalcaemia in Williams-Beuren syndrome.
Lameris AL; Geesing CL; Hoenderop JG; Schreuder MF
J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):757-61. PubMed ID: 24572979
[TBL] [Abstract][Full Text] [Related]
7. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
McIntyre HD; Cameron DP; Urquhart SM; Davies WE
Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
[TBL] [Abstract][Full Text] [Related]
8. An audit of the management of malignant hypercalcaemia.
Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
[TBL] [Abstract][Full Text] [Related]
9. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
10. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Gurney H; Kefford R; Stuart-Harris R
Lancet; 1989 Jul; 2(8657):241-4. PubMed ID: 2569054
[TBL] [Abstract][Full Text] [Related]
11. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Wimalawansa SJ
Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
[TBL] [Abstract][Full Text] [Related]
12. Pamidronate for long-term control of hypercalcemia associated with Williams syndrome.
Ismail J
Indian Pediatr; 2015 Feb; 52(2):163-4. PubMed ID: 25691196
[No Abstract] [Full Text] [Related]
13. Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronate.
Newrick PG; Braatvedt GD; Webb AJ; Sheffield E; Corrall RJ
Postgrad Med J; 1994 Mar; 70(821):231-2. PubMed ID: 8183761
[TBL] [Abstract][Full Text] [Related]
14. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
[TBL] [Abstract][Full Text] [Related]
15. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
16. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
17. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia.
Dodwell DJ; Howell A; Morton AR; Daley-Yates PT; Hoggarth CR
Postgrad Med J; 1992 Jun; 68(800):434-9. PubMed ID: 1437922
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
19. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
Sawyer N; Newstead C; Drummond A; Cunningham J
Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
[TBL] [Abstract][Full Text] [Related]
20. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate.
Illidge TM; Hussey M; Godden CW
Clin Oncol (R Coll Radiol); 1996; 8(4):257-8. PubMed ID: 8871006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
